Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Structure-based design of thrombin inhibitors.

Roland Pfau1

  • 1Boehringer Ingelheim Pharma GmbH & Co KG, Department of Chemical Research, Birkendorfer Strasse 65, D-88397 Biberach an der Riss, Germany. Roland.Pfau@bc.Boehringer-Ingelheim.com

Current Opinion in Drug Discovery & Development
|September 4, 2003
PubMed
Summary

Developing effective anticoagulatory therapies remains a challenge. This review focuses on small-molecule thrombin inhibitors, addressing challenges in creating marketable drugs with optimal pharmacokinetic and physicochemical profiles.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Communicative Adaptations After Laryngectomy: Syntactic Complexity and Gesture Use.

International journal of language & communication disorders·2026
Same author

Towards holistic Compound Quality Scores: Extending ligand efficiency indices with compound pharmacokinetic characteristics.

Drug discovery today·2023
Same author

Negation and Negative Concord in Georgian Sign Language.

Frontiers in psychology·2022
Same author

Identification of Highly Selective Orexin 1 Receptor Antagonists Driven by Structure-Based Design.

Journal of chemical information and modeling·2021
Same author

Structure and Grammaticalization of Serial Verb Constructions in Sign Language of the Netherlands-A Corpus-Based Study.

Frontiers in psychology·2018
Same author

Event representations constrain the structure of language: Sign language as a window into universally accessible linguistic biases.

Proceedings of the National Academy of Sciences of the United States of America·2015

Area of Science:

  • Pharmacology
  • Medicinal Chemistry
  • Drug Development

Background:

  • Thromboembolic events are a leading cause of death globally.
  • Current anticoagulatory therapies have limitations in preventing these events effectively.
  • Thrombin plays a critical role in clot formation and platelet activation.

Purpose of the Study:

  • To review the development of small-molecule thrombin inhibitors.
  • To highlight the challenges in achieving optimal pharmacokinetic and physicochemical properties for these inhibitors.
  • To focus on strategies for creating marketable anticoagulant drugs.

Main Methods:

  • Structure-based design of potent thrombin inhibitors.
  • Review of pharmacokinetic and physicochemical profiling strategies.

Related Experiment Videos

  • Analysis of current drug development challenges in anticoagulation.

    • Main Results:

    • Potent thrombin inhibitors have been designed using structural data.
    • Significant challenges remain in optimizing drug-like properties for clinical application.
    • The focus is on overcoming these hurdles for marketable drug development.

    Conclusions:

    • Small-molecule thrombin inhibitors offer a promising therapeutic strategy.
    • Achieving favorable pharmacokinetic and physicochemical profiles is crucial for clinical success.
    • Further research is needed to translate potent inhibitors into effective, marketable anticoagulant drugs.